- 期刊
評估「樂亦康®膠囊」之免疫調節功能
Immunomodulatory Effects of ＂eN-Lac Capsule＂ in BALB/c Mice
摘要
本試驗目的在探討「樂亦康®膠囊」對於非特異性免疫反應和特異性免疫反應之調節作用。動物隨機分成4組，分別為（A組）負對照組、（B組）低劑量組（0.25倍試驗物質，51.25 mg/kg）、（C組）中劑量組（1倍試驗物質，205.0 mg/kg）與（D組）高劑量組（2.5倍試驗物質，512.5 mg/kg）。本試驗使用7週齡雌性SPF級BALB/c小鼠以每日管餵方式，連續9週餵食不同劑量的試驗物質。在非特異免疫反應試驗模式下，低劑量組可促進細胞激素IFN-和IL-10分泌量、減少血清中IgG1分泌量。中劑量組可促進脾臟淋巴細胞增生活性（Untreated和Con A刺激條件下）、促進細胞激素IL-2、IFN-和IL-10分泌量、減少血清中IgG1分泌量。高劑量組可促進脾臟淋巴細胞增生活性（Untreated和Con A刺激條件下）、促進細胞激素IL-2、IFN-和IL-10分泌量、促進血清中IgG2a分泌量、減少血清中IgG1分泌量。至於特異性免疫試驗方面，實驗第4週以弗氏完全佐劑（complete Freund's adjuvant）以及第5.5和7週以弗氏不完全佐劑（incomplete Freund's adjuvant）搭配抗原（卵白蛋白，OVA）誘導小鼠，建立OVA特異性免疫的動物模式。在特異免疫反應試驗模式下，低劑量組可促進特異性IgG抗體生成、減少血清OVA特異性IgG1抗體分泌量（ELISA unit, E.U.）。中、高劑量組可促進OVA 特異性總脾臟淋巴細胞增生、促進血清OVA特異性IgG抗體分泌量、減少血清OVA特異性IgE和IgG1抗體分泌量。總結以上結果，在非特異及特異性免疫反應試驗模式下，景岳生物科技股份有限公司所提供之「樂亦康®膠囊」具有促進淋巴細胞增生、調節細胞激素分泌、促進IgG2a抗體生成、促進特異性IgG抗體生成的功效。
並列摘要
The purpose of this study is to evaluate the immune modulating properties of ＂eN-Lac capsule＂ regarding to non-specific immune responses and specific immune responses. The animals were randomly divided into four groups, there were (A) negative control group, (B) low-dose group (0.25-fold dosage, 51.25 mg/kg), (C) middle-dose group (1-fold dosage, 205.0 mg/ kg) and (D) high-dose group (2.5-old dosage, 512.5 mg/kg), respectively. Seven-week-old female BALB/c mice were treated with various quantities test article by orally administered for 9 weeks. In the non-specific immune responses, the low-dose group increased cytokine IFNand IL-10 secretion and reduced serum IgG1 secretion. Middle-dose group elevated spleen lymphocyte proliferative activity (Untreated and Con A conditions), cytokines IL-2, IFN- , IL-10 secretion, and decreased the secretion of serum IgG1. High-dose group promoted spleen lymphocyte proliferative activity (Untreated and Con A conditions), cytokines IL-2, IFN-γ, IL-10 secretion, secretion of serum IgG2a, and reduced secretion of serum IgG1. In the specific immune responses, mice were immunized with antigen (ovalbumin, OVA) and complete Freund's adjuvant on week 4. On week 5.5 and week 7, mice were immunized with OVA and incomplete Freund's adjuvant, and established the OVA-specific animal model. In the specific immune responses, low-dose group promoted specific IgG antibody production, reduced OVA-specific IgG1 antibody secretion (ELISA unit, EU). Medium and highdose groups increased OVA-specific splenocyte proliferation, secretion of OVA-specific IgG antibody, and decreased OVA-specific IgE and IgG1 antibodies secretion. In summary, under the conditions designed for the non-specific and the specific immune responses study on ＂eNLac capsule＂, we found that was associated with significant enhancement of lymphocytes proliferation, cytokine regulation, and the secretions of IgG2a antibody and specific IgG antibody.